Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases

CONCLUSION: Sorafenib therapy was well-tolerated and provided about 3 months longer median OS in our patients with advanced HCC than those treated with BSC alone.

Source: Indian Journal of Cancer - May 24, 2018 Category: Cancer & Oncology Authors: KN Lokesh Tamojit Chaudhuri KC Lakshmaiah K Govind Babu Lokanatha Dasappa Linu Abraham Jacob MC Suresh Babu AH Rudresha LK Rajeev Source Type: research